Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CHF 5993 pMDI in Renal Impairment
NCT02040597Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Glycopyrrolate Area Under the Curve at 72 hours. Started Jan 2014; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02040597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040597.